Claudio Giovanni De Angelis

Prof. Dr. Claudio Giovanni De Angelis

Endoscopy and Endosonography Center Gastroenterology department, Città della Salute e della Scienza di Torino, University of Turin, Italy
+1

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Davide Giuseppe RibaldoneDavide Giuseppe Ribaldone
Davide Giuseppe Ribaldone
Sharmila FagooneeSharmila Fagoonee
Sharmila Fagoonee
MAMarco Astegiano
Marco Astegiano
Marilena DurazzoMarilena Durazzo
Marilena Durazzo
AMAnna Morgando
Anna Morgando
Rinaldo PellicanoRinaldo Pellicano
Rinaldo Pellicano
The most commonly used regimens fail to eradicate Helicobacter pylori (H. pylori) infection in 5–10% of patients. Those not cured with treatments based on amoxicillin, clarithromycin, nitroimidazoles, fluoroquinolones, bismuth or tetracycline have no other conventional options thereafter. In this prospective long-term monocentric study, patients who failed to eradicate H. pylori following treatment with all conventional antibiotics were included. All subjects were treated with rifabutin 150 mg, amoxicillin 1 g and a standard dose of proton pump inhibitor, twice daily for 14 days. A negative 13C-urea breath test was used four weeks after treatment completion as an index of H. pylori eradication. Three hundred and two patients were included. Fifty-four percent (164/302) had peptic ulcer disease while 45.7% (138/302) had gastritis or functional dyspepsia. Per-protocol eradication and intention-to-treat eradication were achieved in 72.7% and 71.5%, respectively. A univariate analysis showed that gender, ethnic background, smoking habits and familial history of gastric diseases were not predictive factors of response, while with multiple logistic regression analysis, the ethnic background (Italian) predicted a poor response in the second period of the study (2010–2017). In conclusion, this study on a large cohort of very difficult-to-treat patients showed that rifabutin-based rescue therapy is an acceptable and safe strategy after multiple eradication failures with conventional antibiotics.

22 August 2013 in Nutrients
Verified
Journal Article
Open access
PDF file
Rinaldo PellicanoRinaldo Pellicano
Rinaldo Pellicano
CAClaudio Giovanni De Angelis
Claudio Giovanni De Angelis
Davide Giuseppe RibaldoneDavide Giuseppe Ribaldone
Davide Giuseppe Ribaldone
Sharmila FagooneeSharmila Fagoonee
Sharmila Fagoonee
MAMarco Astegiano
Marco Astegiano
Celiac disease is a chronic, immune-mediated disorder, characterized by small intestinal inflammation and villous atrophy after the ingestion of gluten by genetically susceptible individuals. Several extraintestinal manifestations have been associated to celiac disease. Eosinophilic esophagitis is a primary disorder of the esophagus characterized by upper gastrointestinal symptoms, absence of gastroesophageal reflux disease and more than 15 eosinophils per high-power field in biopsy specimens. Both celiac disease and eosinophilic esophagitis are caused by aberrant, but distinct, immune responses to ingested antigens and can be responsive to restricted food intake. The aim of this review is to assess whether there is an association between these two pathologies. In the majority of the studies examined, including the studies in pediatric population, the prevalence of eosinophilic esophagitis in subjects with celiac disease was about 10-times that of the general population. We suggest searching for eosinophilic esophagitis in all children undergoing endoscopy for suspicious celiac disease.

1 January 2015 in World Journal of Gastrointestinal Endoscopy
Verified
Journal Article
Open access
CAClaudio Giovanni De Angelis
Claudio Giovanni De Angelis
MMMilena Marietti
Milena Marietti
MBMauro Bruno
Mauro Bruno
RPRinaldo Pellicano
Rinaldo Pellicano
MRMario Rizzetto
Mario Rizzetto
Endoscopic ultrasound in common bile duct dilatation with normal liver enzymes

21 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CAClaudio Giovanni De Angelis
Claudio Giovanni De Angelis
PVPablo Cortegoso Valdivia
Pablo Cortegoso Valdivia
SRStefano Rizza
Stefano Rizza
LVLudovica Venezia
Ludovica Venezia
FRFelice Rizzi
Felice Rizzi
Rinaldo PellicanoRinaldo Pellicano
Rinaldo Pellicano
Endoscopic injection of glues, clotting factors, or sclerosing agents is a well-known therapy for the treatment of non-variceal upper gastrointestinal bleeding (NVUGIB), but less is known about endoscopic ultrasound (EUS)-guided treatments. In this setting, literature data are scarce, and no randomized controlled trials are available. We performed a review of the existing literature in order to evaluate the role of EUS-guided therapies in the management of NVUGIB. The most common treated lesions were Dieulafoy’s lesions, pancreatic pseudoaneurysms, and gastrointestinal stromal tumors (GISTs). Mostly, the treatments were performed as a salvage option after failure of conventional endoscopic hemostatic attempts, showing good efficacy and a good safety profile, also documented by Doppler monitoring of treated lesions. EUS-guided therapies may be an effective option in the treatment of refractory NVUGIB, thus avoiding radiological or surgical management. Nevertheless, available literature still lacks robust data.

1 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MGMarcantonio Gesualdo
Marcantonio Gesualdo
FRFelice Rizzi
Felice Rizzi
SBSilvia Bonetto
Silvia Bonetto
SRStefano Rizza
Stefano Rizza
FCFederico Cravero
Federico Cravero
CAClaudio Giovanni De Angelis
Claudio Giovanni De Angelis
Gut microbiota represent an interesting worldwide research area. Several studies confirm that microbiota has a key role in human diseases, both intestinal (such as inflammatory bowel disease, celiac disease, intestinal infectious diseases, irritable bowel syndrome) and extra intestinal disorders (such as autism, multiple sclerosis, rheumatologic diseases). Nowadays, it is possible to manipulate microbiota by administering prebiotics, probiotics or synbiotics, through fecal microbiota transplantation in selected cases. In this scenario, pancreatic disorders might be influenced by gut microbiota and this relationship could be an innovative and inspiring field of research. However, data are still scarce and controversial. Microbiota manipulation could represent an important therapeutic strategy in the pancreatic diseases, in addition to standard therapies. In this review, we analyze current knowledge about correlation between gut microbiota and pancreatic diseases, by discussing on the one hand existing data and on the other hand future possible perspectives.

28 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ARAngela Dalia Ricci
Angela Dalia Ricci
SPSara Pusceddu
Sara Pusceddu
Francesco PanzutoFrancesco Panzuto
Francesco Panzuto
FGFabio Gelsomino
Fabio Gelsomino
Sara MassironiSara Massironi
Sara Massironi
DCDavide Campana
Davide Campana
Rectal neuroendocrine tumors (r-NETs) are rare tumors with overall good prognosis after complete resection. However, there is no consensus on the extension of lymphadenectomy or regarding contraindications to extensive resection. In this study, we aim to identify predictive factors that correlate with nodal metastasis in patients affected by G1–G2 r-NETs. A retrospective analysis of G1–G2 r-NETs patients from eight tertiary Italian centers was performed. From January 1990 to January 2020, 210 patients were considered and 199 were included in the analysis. The data for nodal status were available for 159 cases. The nodal involvement rate was 9%. A receiver operating characteristic (ROC) curve analysis was performed to identify the diameter (>11.5 mm) and Ki-67 (3.5%), respectively, as cutoff values to predict nodal involvement. In a multivariate analysis, diameter > 11.5 mm and vascular infiltration were independently correlated with nodal involvement. A risk scoring system was constructed using these two predictive factors. Tumor size and vascular invasion are predictors of nodal involvement. In addition, tumor size > 11.5 mm is used as a driving parameter of better-tailored treatment during pre-operative assessment. Data from prospective studies are needed to validate these results and to guide decision-making in r-NETs patients in clinical practice.